Questions and answers on the use of dabigatran and perpectives on the use of other new oral anticoagulants in patients with atrial fibrillation; a consensus document of the Italian federation of thrombosis centers (FCSA)
Thrombosis and Haemostasis, ISSN: 0340-6245, Vol: 106, Issue: 5, Page: 868-876
2011
- 172Citations
- 151Captures
- 1Mentions
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations172
- Citation Indexes168
- 168
- CrossRef121
- Clinical Citations2
- PubMed Guidelines2
- Policy Citations2
- Policy Citation2
- Captures151
- Readers151
- 139
- 12
- Mentions1
- References1
- Wikipedia1
Article Description
Dabigatran and other new oral anticoagulants (OAC) represent a step forward in stroke prevention in patients with atrial fibrillation (AF). They indeed have been shown to be an alternative to vitamin K antagonists (VKAs) without the burden of laboratory control. However, these new drugs compete with an effective and well-established therapy, thus bringing about a series of questions and doubts. In this report members of the board of the Italian Federation of Thrombosis Centers (FCSA) answer some questions every clinician might be confronted with. © Schattauer 2011.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=80155206426&origin=inward; http://dx.doi.org/10.1160/th11-05-0358; http://www.ncbi.nlm.nih.gov/pubmed/21946939; http://www.thieme-connect.de/DOI/DOI?10.1160/TH11-05-0358; http://www.schattauer.de/index.php?id=1214&doi=10.1160/TH11-05-0358; http://www.schattauer.de/index.php?id=5236&mid=16730&L=1; https://dx.doi.org/10.1160/th11-05-0358; https://www.thieme-connect.de/products/ejournals/abstract/10.1160/TH11-05-0358
Georg Thieme Verlag KG
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know